VIVES is a multi-sector fund that invests in projects with a positive societal impact
To meet the growing demand for agricultural production, traditional production methods will have to be complemented by new technologies that not only improve crop yields, but also increase their...
Founded in 2020, Brightflow is a medical device startup company based in Paris, France. The team’s vision is to bring to market the first long-term mechanical assist device to support RV failure...
Promethera Biosciences’ mission is to bring patients life-saving treatments to reduce the need for liver transplantation. The company is pioneering the development of cell-based therapies that provide...
Vincent Mouret, Chairman of the board of Cissoid :
"As Chairman of the board of Cissoid, I’ve been working closely to VIVES for the last 10 years.
I have really appreciated VIVES involvement and...
Willem de Vos, Professor at University of Wageningen ; Patrice Cani, Professor at UCLouvain ; Jean-Christophe Malrieu, CEO A-Mansia :
"As founders and CEO of A-mansia Biotech we experienced essential...
David Frenay, CEO Emolytics :
"Emolytics is a spin-off of the UCLouvain, founded in 2014 and acquired by Profacts in 2018. Emolytics has been supported by VIVES II Fund since its inception, as VIVES...
Proceeds will advance clinical development of Nuclidium’s true theranostic pipeline and expand its global production and manufacturing network for copper-based radiopharmaceuticals
Participation is
NVD003 is a bone grafting material developed to surgically treat patients with Congenital Pseudarthrosis of the Tibia, a rare and difficult-to-treat pediatric disease
Four young patients were treated
VIVES Partners’ portfolio investment The Akkermansia Company (TAC) acquired by Danone
Acquisition of TAC’s gut microbiota product, with benefits for people at risk of cardiovascular disease